The future of AI drug discovery & development in immunology and GPCR research
pharmaphorum
SEPTEMBER 16, 2022
Essentially, the collaboration brought together both “the right expertise and the right technology”, opening up myriad possibilities for targeting GPCRs within the human genome. A notable issue with clinical trials is the homogeneity of the patient database. What, then, is the solution? About the interviewee.
Let's personalize your content